Walmart recalls frozen shrimp over potential radioactive contamination
The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia.
The products could pose a 'potential health concern' for people exposed to low levels of Cesium-137 over time, FDA officials said.
'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away,' FDA officials said in a statement.
The risk from the recalled shrimp is 'quite low,' said Donald Schaffner, a food safety expert at Rutgers University.
Cesium-137 is a byproduct of nuclear reactions, including nuclear bombs, testing, reactor operations and accidents. It's widespread around the world, with trace amounts found in the environment, including soil, food and air.
The level detected in the frozen breaded shrimp was far lower than FDA intervention levels. However, the agency said that avoiding potentially contaminated products could reduce exposure to low-level radiation that could lead to health problems over time.
The FDA is investigating reports of Cesium-137 contamination in shipping containers and products processed by P.T. Bahari Makmur Sejati, doing business as BMS Foods of Indonesia. U.S. Customs and Border Protection officials alerted FDA that they found Cesium-137 in shipping containers sent to U.S. ports in Los Angeles, Houston, Miami and Savannah, Georgia.
FDA officials collected several product samples and detected contamination in one sample of frozen breaded shrimp. The shipping containers and products were denied entry into the U.S.
However, the FDA then learned that Walmart had received potentially affected products imported after the first detection, from shipments that did not trigger contamination alerts.
Walmart immediately recalled the products, a company spokesperson said. They include Great Value brand frozen raw shrimp with lot codes 8005540-1, 8005538-1 and 8005539-1, all with best-by dates of March 15, 2027. The shrimp was sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Consumers should discard the products or return them to any Walmart store for refund.
___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
First PRIZM Study Participant Enrolled in Tisento Therapeutics' Open-Label Extension Study in MELAS
Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to Enroll CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the first participant has enrolled in the company's open-label extension study in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes). The extension study (NCT06961344) is evaluating the long-term safety and tolerability of zagociguat in individuals with MELAS who complete treatment in the global Phase 2b PRIZM study, which is expected to complete screening in the next months. The extension study is intended to provide uninterrupted access to zagociguat for clinical trial participants for up to two years and evaluate the long-term safety of zagociguat. 'We're pleased to reach the important milestone of enrolling the first PRIZM study participant into our open-label extension study,' said Peter Hecht, Ph.D., chief executive officer of Tisento. 'Enthusiastic engagement by MELAS patients and physicians is powering momentum in our development program, and we look forward to completing PRIZM enrollment in the next few months.' The PRIZM study is actively enrolling in the U.S., Canada, Australia, United Kingdom, Italy, and Germany, and interested individuals are encouraged to discuss participation with their physician. PRIZM is evaluating the impact of zagociguat treatment on fatigue, cognitive performance, and other key aspects of MELAS. The clinical outcome assessments and endpoint strategy for the PRIZM study were informed by Tisento's interview study in which individuals living with MELAS described the symptoms and impacts of the disease that are most important to them. Participants who complete treatment in PRIZM have the opportunity to enroll in the open-label extension study. About the PRIZM Study PRIZM – a Phase 2b Randomized, Placebo-Controlled Trial Investigating Zagociguat in MELAS – is evaluating the efficacy and safety of oral zagociguat 15 mg or 30 mg compared to placebo when administered once-daily for 12 weeks in participants with genetically and phenotypically defined MELAS. The PRIZM study has a crossover design, with two 12-week treatment periods separated by a 4-week washout period. All participants will receive zagociguat during one of the 12-week periods and placebo during the other. Participants who complete treatment in the study have the opportunity to enroll in an open-label extension study. The global PRIZM study is now enrolling approximately 44 participants at mitochondrial disease centers of excellence in the U.S., Italy, Germany, United Kingdom, Australia, and Canada. For more information, please visit or (NCT06402123). Interested individuals can also reach out to their physicians for participation details. About Zagociguat Zagociguat is a once-daily, oral, clinical-stage investigational medicine with potential to positively impact both peripheral and central nervous system manifestations of mitochondrial diseases. Zagociguat stimulates soluble guanylate cyclase (sGC), an enzyme that is found in virtually every cell in every tissue of the body and is part of a system of cellular mechanisms that control critical physiological functions including neuronal function and blood flow. A first-in-class, brain-penetrant sGC stimulator, zagociguat is hypothesized to rebalance dysregulated cellular pathways in MELAS. By restoring cellular functions that support mitochondria, zagociguat may help restore mitochondrial energy production and physiological function. In a Phase 2a study in patients with MELAS, zagociguat exhibited a favorable safety profile, exposure throughout the body including in the central nervous system, and improvements in neuronal function, mitochondrial function, and blood flow in the brain. Zagociguat is currently being evaluated as a treatment for MELAS in the Phase 2b PRIZM study. Zagociguat received Fast Track designation from the U.S. Food and Drug Administration for the treatment of MELAS. Fast Track is a process designed to facilitate the development and potentially expedite the review of medicines to treat serious conditions and fill an unmet medical need, with the goal of getting important new drugs to patients earlier. For more information, visit About Tisento Therapeutics Tisento Therapeutics, a privately held biotech company, is developing novel medicines to treat diseases with significant unmet need, beginning with MELAS and other genetic mitochondrial diseases. Ti sento means 'I hear you' in Italian; our approach to innovation begins with listening to patients and then channeling what we learn into decisive actions that shape our research and clinical programs. Tisento is guided by a high-caliber internal team of biopharma veterans and an extensive external network of expert physicians, patient advocacy groups, researchers, industry-leading vendors, and other close collaborators who are partners in our mission to develop meaningful treatments for mitochondrial diseases. Learn more at our website, or connect with us on LinkedIn, Facebook, X (@tisentotx), or Bluesky. Contact Tisento Media RelationsJessi Rennekamp, Astrior CommunicationsEmail: jessi@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
This Advice From Economics Might Be The Answer To Your Parenting Burnout. Here's Why.
When my wife and I brought our first child home from the hospital, we planned on diligently following all of the expert recommendations regarding his care: He would breastfeed exclusively and sleep in a bassinet beside our bed, on his back, in a properly ventilated room. We had read about SIDS and would take every possible precaution. What could be more important that preventing harm from coming to our child? Almost immediately, however, we ran into trouble. Our baby stopped peeing. He was dehydrated and hungry, somehow, although he spent pretty much all day at my breast. So we feed him some infant formula using a medicine dropper, which he lapped up hungrily, sending me into a shame spiral that took months of therapy to crawl out of. But at least with the supplementary formula we were able to keep him happily fed. Related: The second problem sent us into a territory that was even more mortifying. In spite of the fact that my breasts were only partially functional, the baby was extremely attached to them. As in, he would only sleep if they were right there, right beside him, skin to skin with his tiny cheek. Every time he feel asleep while nursing and unlatched his little rosebud lips, I moved as stealthily as possible to try to get him into the bassinet. But more often than not, he woke and started crying. And even if I could get him to lie in the bassinet, it often didn't last long. The end result was that I spent a lot of time nursing him in the chair, and, in my desperation and exhaustion, I often fell asleep. My wife could tell, just by looking at us, that this was not a safe situation. Since it wasn't possible to get him into the bassinet, we just cleared our bed of blankets and pillows and let him sleep where he wanted to, right next to my body. We didn't tell anyone. We had been taught that bed-sharing with a baby was deadly, so we certainly weren't going to admit to doing it. This was all back in 2009, before economist Emily Oster began publishing her bestselling books, in which she brings a unique, data-driven perspective to the art of parenting. In her second book, 'Cribsheet,' she explains how holding up the ideal infant sleeping arrangement as the only permissible option can actually lead parents to put their babies in more danger. Because although it is safest to have baby sleep on a separate surface, it is much more dangerous to sleep with a baby on a sofa or armchair. Sixty-seven times more dangerous. Though it wasn't a best-case scenario that the baby wasn't in the bassinet, he was a lot safer sleeping next to me on the mattress instead of in the recliner. Infant sleep, Oster writes, is one example of a scenario in which we might benefit from considering what she calls 'second best' parenting. It is a term she borrows from economics. 'When we are giving advice in parenting, we tend to be absolutist: There is the best option and then everything else,' Oster told HuffPost, She has used the term 'outer darkness' to refer to everything else — as in, if it's not the best option, it's all equally bad and scary. But this all-or-nothing approach doesn't apply well to infant sleep, where we clearly have a first best option (bassinet/crib in same room as parent) followed by a second best option (on a clear, flat sleeping surface next to the nursing parent) and then, way, way down, the 67th best option of a desperate mother accidentally falling asleep in an armchair while holding the baby because she has been told that under no circumstances should she consider bringing the baby into her bed. 'The idea of 'second best' is to recognize that within the category of 'other options,' some are better than others. The second best is the best option that we can achieve,' Oster said. She thinks that this can be a useful framework for other parenting choices, too, such as what to feed our children. 'We're told the best snack for our kids is, say, a whole apple and a glass of water. But what if your kid doesn't eat that? We don't help people pick well among the options their child will eat. You'd be forgiven for thinking that once you're going to applesauce, you might as well give a pile of cookies. But actually those aren't the same.' Believing that there is only one right way and the rest are wrong sets us up to see only black and white when actually there are so many shades of gray. 'When we tell people that it's the 'best or the rest,' we do not allow for them to choose smartly among the rest,' Oster said. In addition to not choosing well, this thinking makes people feel badly about how they're parenting. 'When we tell people they aren't doing their best, that disempowers them. And no one parents well from a place of shame,' Oster added. Finding Other Good Options Beyond Perfect The advantage of referring to 'second best' is that, with the word 'best,' parents are left with space to take pride in their parenting. A silver or bronze medal is still a win, after all. The argument that Oster is making is similar to that of 'good enough parenting,' an idea popularized in the 1950s by Donald Winnicott. Parenting coach Kristene Geering told HuffPost that this is the framework she uses with parents. 'It's based on the notion that there is no such thing as perfect,' Geering explained. 'Part of being human is that there are challenges, there are times when there's no clear or easy path (which is also how we learn). There is no 'best.' You take what information you have, make a decision based on that and then you learn as you go along.' Geering thinks this dovetails nicely with Carol Dweck's 'growth mindset,' in which as we learn more, we do better. Geering said she often tells families that 'we're all doing the best we can with what we have' and advises, 'Learn from your mistakes, repair as you go, and show your children how to hold compassion for yourself and those around you.' She likes the 'good enough' phrasing because it makes room for the idea that there are many different options that might be 'bests' for different families dealing with different circumstances. Geering agrees with Oster that it's important to move parents out the space of 'all is lost,' where they may get trapped in their shame. She said that where she works in Silicon Valley, 'I see a lot of parents fall into this trap of trying to be 'perfect' ... and then researching themselves into a state where they're almost frozen with indecision.' With an endless amount of information readily available, this isn't an uncommon place for parents to land. 'I've fallen into this trap as well,' Geering admitted. 'Things like which school to attend, which activity to sign up for... it's really overwhelming.' Make Peace With Your 'Good Enough' Using a 'second best' or 'good enough' mindset doesn't come naturally to people raised in a culture of competition. But sooner or later, all parents are faced with a scenario that challenges expectations of perfection. For Geering, a clear example of this in her own family was pandemic schooling. 'I watched my own kids struggle on 'Zoom school,' to the point where it was clear this would never work for them. So I pulled them, and we did homeschool for a year... while my husband and I both worked full time. Was it perfect? Nope. Was it 'second best'? I have no idea.' Her kids are 'still catching up on math,' she said, although they also 'gained a lot of skills in independence.' 'Instead of beating myself up on all the math they missed out on, I looked at it from the point of view that I was doing the best I could in really awful circumstances. And I looked at all the moms in my friend groups and the parents I was working with, and I saw everyone making different decisions, based on their specific circumstances. Absolutely no one did the 'best' thing... because there was no 'best' thing.' Whether you think of it as 'second best' or 'good enough,' parenting within this framework, as opposed to one in which there is only one right option for all families, makes room for you to give yourself some grace. An added benefit of letting go of a perfection-or-nothing mindset is the weight that this takes off of our kids. If we 'show them how to repair the relationship when we mess up and share our learning process with them,' Geering said, 'it lets them be compassionate with themselves, learn from their mistakes, create authentic and meaningful relationships with others, and have a growth mindset as their default throughout life. That's pretty powerful stuff.' Related... Parents Are Lying About Where Their Babies Sleep At Night. Here's Why That's A Problem. What Second-Time Parents Wish They Didn't Stress About The First Time Around This 1 Thing May Be Wearing Parents Out Everywhere
Business Wire
29 minutes ago
- Business Wire
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. The hold was lifted in under three months, underscoring the efficiency of the FDA's review process and Rocket's commitment to expeditiously optimize safety and resume the trial. In its correspondence, the FDA confirmed that Rocket satisfactorily addressed issues outlined in the clinical hold. The FDA authorized the pivotal study to resume first with a recalibrated dose of 3.8 x 10¹³ GC/kg of RP-A501 in three patients, treated sequentially with a minimum four-week interval between each treatment. This adjusted dose aligns with the lower range of administered doses that were associated with efficacy across multiple biomarkers, echocardiographic and clinical endpoints in the Phase 1 study, and has been determined as most likely to confer the safety and efficacy identified in the low-dose Phase 1 cohorts. In addition, Rocket will collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort. The revised regimen discontinues prophylactic use of a C3 complement inhibitor, while maintaining sirolimus, rituximab, and steroids. Additionally, the protocol will specify a lower threshold for administering a C5 inhibitor (eculizumab) in response to impending complement activation. To date, six patients with Danon disease have been treated in the Phase 2 study with RP-A501. Further updates about the Phase 2 study can be expected following review of data from the next three patients. RP-A501 Phase 2 Pivotal Trial Overview The global, single-arm, multi-center 12-patient Phase 2 pivotal trial evaluates the efficacy and safety of RP-A501 for the treatment of Danon disease. The trial began with a pediatric safety run-in (n=2) and treated a total of six patients at a dose level of 6.7 x 10 13 GC/kg. Per alignment with the FDA upon lifting of the clinical hold, three additional patients are expected to be treated at a dose level of 3.8 x 10 13 GC/kg with a minimum four-week interval between dosing, followed by additional patients to complete the trial. To support accelerated approval, the study assesses the efficacy of RP-A501 as measured by the biomarker-based co-primary endpoint consisting of improvements in LAMP2 protein expression, and reductions in left ventricular mass. The key secondary endpoint is change in troponin. Additional secondary endpoints include natriuretic peptides, Kansas City Cardiomyopathy Questionnaire, New York Heart Association class, event free survival to 24 months and treatment emergent safety events. These endpoints could support full approval with longer-term follow-up. A global natural history study is running concurrently with the Phase 2 pivotal trial. All patients enrolled in the trial are required to have a three-months observational pre-treatment run-in to enable an assessment of troponin (and other biomarker) trajectories to optimally assess this key secondary endpoint. Details about the Phase 2 study can be found at under NCT identifier NCT06092034. About RP-A501 RP-A501 is Rocket's investigational gene therapy for the treatment of Danon disease and the first gene therapy for a cardiovascular condition to demonstrate safety and efficacy in clinical studies. RP-A501 has the potential to restore or stabilize cardiac function in patients with Danon disease. RP-A501 consists of a recombinant adeno-associated serotype 9 (AAV9) capsid containing a functional version of the human LAMP2B transgene ( which is administered as a single intravenous (IV) infusion. In clinical studies, RP-A501 has been shown to target cardiac cells (cardiomyocytes) and deliver the functional LAMP2B gene to heart tissue, which led to improved cardiac structure and function in patients. RP-A501 holds FDA RMAT, Fast Track, Rare Pediatric, and Orphan Drug designations in the U.S. along with ATMP and PRIME designations in the EU. About Danon Disease Danon disease is a rare X-linked inherited, multi-organ lysosomal-associated disorder with a devastating clinical course. The causative mutation has been identified in the gene encoding for lysosome-associated membrane protein, otherwise known as LAMP2, an important mediator of autophagy and primarily expressed in heart, skeletal muscle and brain tissue. This mutation results in accumulation of autophagosomes and glycogen, particularly in cardiac muscle and other tissues, which ultimately leads to heart failure, and for male patients, frequent death during adolescence or early adulthood. The only available treatment option for Danon disease is cardiac transplantation, which is associated with substantial complications and is not considered curative, representing the high unmet medical need for patients with Danon disease. It is estimated to have a prevalence of 15,000 to 30,000 patients in the U.S. and Europe. In 2023, Rocket secured an ICD-10 code from the Centers for Medicare and Medicaid Services (CMS) to document patients with LAMP2 deficiency in Danon disease. About Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket's innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives. Rocket's adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage clinical program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, and an early-stage clinical program for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death. Rocket has also received IND clearance for its AAV-based gene therapy for BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles. Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. For more information about Rocket, please visit and follow us on LinkedIn, YouTube, and X. Rocket Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements concerning Rocket's future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as 'could,' 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'will give,' 'estimate,' 'seek,' 'will,' 'may,' 'suggest' or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket's ongoing and planned clinical trials, the expected timing and outcome of Rocket's regulatory interactions and planned submissions, including the timing and outcome of the FDA's review of the additional CMC information that Rocket will provide in response to the FDA's request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket's ability to establish key collaborations and vendor relationships for its product candidates, Rocket's ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket's ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket's ability to transition to a commercial stage pharmaceutical company, and Rocket's expectation that its cash, cash equivalents and investments will be sufficient to fund its operations into the second quarter of 2027. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket's competitors' activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket's ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket's ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket's ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled 'Risk Factors' in Rocket's Annual Report on Form 10-K for the year ended December 31, 2024, filed February 27, 2025 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
